Altamira Therapeutics Ltd. filings document its reporting as a Bermuda foreign private issuer developing peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues. Form 6-K reports include unaudited condensed consolidated interim financial statements, management discussion and analysis, press releases, and Inline XBRL exhibits.
The company’s regulatory record also references Form F-3 and Form S-8 registration statements, including filings made under its former Auris Medical Holding Ltd. name. Disclosures cover operating results, liquidity, capital structure, registered securities, equity compensation, and business updates tied to the OligoPhore™ and SemaPhore™ platforms, AM-401, AM-411, and the Bentrio® interest held through Altamira Medica.